These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 24920926)
1. Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. Yuan Y; Li XF; Chen JQ; Dong CX; Weng SS; Huang JJ Onco Targets Ther; 2014; 7():841-52. PubMed ID: 24920926 [TBL] [Abstract][Full Text] [Related]
2. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Sanford M; Scott LJ Drugs; 2009 Nov; 69(16):2303-28. PubMed ID: 19852530 [TBL] [Abstract][Full Text] [Related]
4. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494 [TBL] [Abstract][Full Text] [Related]
5. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145 [TBL] [Abstract][Full Text] [Related]
6. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Dhillon S Target Oncol; 2015 Mar; 10(1):153-70. PubMed ID: 25637458 [TBL] [Abstract][Full Text] [Related]
7. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T; Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
10. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib. Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492 [TBL] [Abstract][Full Text] [Related]
11. Spotlight on gefitinib in non-small-cell lung cancer. Frampton JE; Easthope SE Am J Pharmacogenomics; 2005; 5(2):133-6. PubMed ID: 15813676 [TBL] [Abstract][Full Text] [Related]
12. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139 [TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
16. Gefitinib: current status in the treatment of non-small cell lung cancer. Tanović A; Alfaro V Drugs Today (Barc); 2004 Oct; 40(10):809-27. PubMed ID: 15605116 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116 [TBL] [Abstract][Full Text] [Related]
18. The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. Suzuki T; Mitsudomi T; Hida T Per Med; 2004 Dec; 1(1):27-34. PubMed ID: 29793222 [TBL] [Abstract][Full Text] [Related]
19. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038 [TBL] [Abstract][Full Text] [Related]